Early cancer drug trial halted after just 3 patients

NCT ID NCT05317078

Terminated Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enrolled, so no clear results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLAUDIN 6-POSITIVE ADVANCED/METASTATIC MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial endometrial cancer malignant testicular germ cell tumor non-small cell lung carcinoma ovarian carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLAUDIN 6-POSITIVE ADVANCED/METASTATIC MALIGNANT SOLID TUMORS EPITHELIAL OVARIAN CANCER NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cabrini Hospital

Malvern, Victoria, 3144, Australia
City of Hope National Medical Center

Duarte, California, 91010, United States
Inselspital Bern

Bern, 3010, Switzerland
Monash Medical Centre

Clayton, Victoria, 3168, Australia
Southern Oncology Clinical Research Unit

Bedford Park, South Australia, 5042, Australia
University of California Irvine

Orange, California, 92868, United States
University of California Los Angeles

Los Angeles, California, 90095-1678, United States
Virginia Commonwealth University

Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.